Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: DPP4


Trends in diabetes medication use in Australia, Canada, England, and Scotland: a repeated cross-sectional analysis in primary care

February 23rd 2021

New drugs are displacing SUs. However, despite evidence of better outcomes, the adoption of SGLT2s lagged behind DPP4s (British Journal of General Practice)

Categories: Medication, News
Tags: DPP4, SGLT2 inhibitors

Categories: Medication
Tags: DPP4, SGLT2 inhibitors

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal disease

December 16th 2020

In this multinational observational study, SGLT2i was associated with a lower risk of HF and CKD versus DPP4i in patients with type 2 diabetes otherwise free from both cardiovascular and renal disease (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Medication, News
Tags: DPP4, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: DPP4, SGLT2 inhibitors

Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors

August 18th 2020

Adherence to and persistence with DPP4 inhibitors is suboptimal but similar across all medications within the class. While in-class switching is uncommon, saxagliptin and alogliptin are the DPP4 inhibitors most commonly switched (Acta Diabetologica)

Categories: Medication, News
Tags: DPP4

Categories: Medication
Tags: DPP4

Effect of dipeptidyl peptidase‐4 inhibitors on complement activation

July 14th 2020

All the 7 DPP‐4 inhibitors tested in the study directly inhibited functional activity of the lectin pathway in a dose‐dependent manner with varying potency in vitro. In vivo, MBL, sMAC, and C4b declined significantly during follow‐up in both groups without significant effect of sitagliptin (Diabetes/Metabolism Research and Reviews)

Categories: Medication, News
Tags: DPP4, DPP4i

Categories: Medication
Tags: DPP4, DPP4i

Persistent whole day meal effects of three dipeptidyl peptidase‐4 inhibitors on glycemia and hormonal responses in metformin‐treated type 2 diabetes

December 2nd 2019

DPP‐4 inhibition has persistent daytime effects on glucose, islet and incretin hormones with no difference between three different DPP‐4 inhibitors (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: DPP4, Type 2 Diabetes

Categories: Medication
Tags: DPP4, Type 2 Diabetes

The future of new drugs for diabetes management

July 19th 2019

The future of the newer classes of glucose-lowering drugs, namely dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose co-transporter-2 (SGLT-2) inhibitors, is being redefined by the large prospective cardiovascular outcome trials (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: DPP4, GLP1, SGLT2 inhibitors

Categories: Medication
Tags: DPP4, GLP1, SGLT2 inhibitors

Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus

December 1st 2018

TZD users showed significantly better insulin sensitivity, whereas DPP-4 inhibitor users secreted more insulin from β-cells under similar glycemic control (Diabetes Therapy)

Categories: Medication, News
Tags: DPP4, Thiazolidinediones, Type 2 Diabetes

Categories: Medication
Tags: DPP4, Thiazolidinediones, Type 2 Diabetes

Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes

November 8th 2018

Discontinuation of treatment with DPP-4 inhibitor should be considered for patients with diabetes when BP is diagnosed; the recently increased use of DPP-4 inhibitors may explain in part the increasing incidence of BP (JAMA Dermatology)

Categories: News, Pathology
Tags: Bullous Pemphigoid, DPP4

Categories: Pathology
Tags: Bullous Pemphigoid, DPP4

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study

November 6th 2018

When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycemia (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: DPP4, Type 2 Diabetes

Categories: Medication
Tags: DPP4, Type 2 Diabetes

Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017

June 7th 2018

In England there is extensive geographical variation in the prescribing of diabetes drugs after metformin, and increasing use of higher‐cost DPP‐4 inhibitors and SGLT‐2 inhibitors compared with low‐cost sulphonylureas. Our findings strongly support the case for comparative effectiveness trials of current diabetes drugs (Diabetes, Obesity and Metabolism)

Categories: Audits, News
Tags: DPP4, metformin, SGLT2 inhibitors, sulfonylureas

Categories: Audits
Tags: DPP4, metformin, SGLT2 inhibitors, sulfonylureas

Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey

April 25th 2018

In Japan, DPP-4is are the preferred first-line OADs, followed by metformin. The key treatment factors and patient characteristics considered when selecting DPP-4is or metformin are similar for both specialists and nonspecialists. These results may prompt further discussion of the differences in T2DM treatment between Japan and other counties (Diabetes Therapy)

Categories: Medication, News
Tags: DPP4, drug-naive, metformin, Prescribing, Type 2 Diabetes

Categories: Medication
Tags: DPP4, drug-naive, metformin, Prescribing, Type 2 Diabetes

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes

April 18th 2018

In patients with type 2 diabetes, the use of SGLT-2 inhibitors or GLP-1 agonists was associated with better mortality outcomes than DPP-4 inhibitors (JAMA)

Categories: Medication, News
Tags: DPP4, GLP1, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: DPP4, GLP1, SGLT2 inhibitors, Type 2 Diabetes

Contrasting effects on the risk of macrovascular and microvascular events associated with anti-hyperglycaemic drugs that enhance sodium excretion and lower blood pressure

March 13th 2018

Three classes of anti-hyperglycaemic medications are distinguished by their urinary sodium excretion-enhancing and blood pressure-lowering actions: long-acting glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors (Diabetic Medicine)

Categories: Medication, News
Tags: DPP4, GLP1, SGLT2 inhibitors

Categories: Medication
Tags: DPP4, GLP1, SGLT2 inhibitors

High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case–control study

November 7th 2017

Non-obese Asian Indian patients with T2DM and on metformin therapy have significantly higher circulating plasma DPP4 levels as compared to non-obese non-diabetic controls, and these levels correlate with fasting insulin and LDL-C levels, upper limb subcutaneous adipose tissue, intra-abdominal adiposity and presence of diabetes (BMJ)

Categories: News, Pathology
Tags: Asian Indians, DPP4, Type 2 Diabetes

Categories: Pathology
Tags: Asian Indians, DPP4, Type 2 Diabetes

Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis

September 11th 2017

In this real-life analysis, the rate of hospitalizations for heart failure was significantly lower for patients initiating an SGLT2 compared with a DPP4 medication, specifically among older patients and those with diabetes complication (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: DPP4, oral antidiabetic, SGLT2 inhibitors

Categories: Cardiovascular
Tags: DPP4, oral antidiabetic, SGLT2 inhibitors

Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients

January 24th 2017

Novel oral GLDs, compared to insulin, were associated with lower risk of all-cause mortality, CVD and severe hypoglycemia. Dapagliflozin was associated with lower risk of both all-cause mortality and CVD, whereas DPP-4i was only associated with lower risk of all-cause mortality (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: DPP4, insulin, Type 2 Diabetes

Categories: Medication
Tags: DPP4, insulin, Type 2 Diabetes

Dipeptidyl peptidase −4 activity is associated with urine albumin excretion in type 1 diabetes

August 29th 2016

Our results indicate that serum DPP-4 activity is associated with albuminuria in type 1 diabetes. This arises the question whether the use of DPP-4 inhibitors might serve as an additional therapeutic strategy to prevent proteinuria in patients with DKD (Journal of Diabetes and Its Complications)

Categories: Nephropathy, News
Tags: albumin, DPP4, Type 1 Diabetes

Categories: Nephropathy
Tags: albumin, DPP4, Type 1 Diabetes

Reduction of serum concentration of FABP4 by sitagliptin in patients with type 2 diabetes mellitus

October 19th 2015

Sitagliptin decreases serum FABP4 level, at least in part, via reduction in the expression and consecutive secretion of FABP4 in adipocytes by direct inhibition of DPP-4

Categories: Medication, News
Tags: DPP4, FABP4, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: DPP4, FABP4, sitagliptin, Type 2 Diabetes

Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young

May 27th 2015

The pathophysiology of HNF1A-diabetes includes exaggerated postprandial glucagon responses and increased fasting DPP-4 enzymatic activity, but normal postprandial incretin responses in both patients with GCK-diabetes and HNF1A-diabetes (European Journal of Endocrinology)

Categories: News, Pathology
Tags: DPP4, incretin, MODY

Categories: Pathology
Tags: DPP4, incretin, MODY

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes

February 2nd 2015

Only prescription medication in U.S. to combine the dual mechanisms of action of SGLT2 and DPP-4 inhibitors to improve glycemic control as an adjunct to diet and exercise. As an add-on to metformin, GLYXAMBI was superior in reducing A1C when compared with either empagliflozin or linagliptin alone (Lilly)

Categories: Medication, News
Tags: DPP4, SGLT2

Categories: Medication
Tags: DPP4, SGLT2
  • 1
  • 2
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Sanofi DiabetesNapp DiabetesNovo NordiskAstraZeneca

Silver Sponsors

Abbott Diabetes CareAmgenAbout Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership